Flotation

Sutro Biopharma, an immunotherapy developer commercialising technology created at Stanford University, has floated on the Nasdaq Global Market.

Principia Biopharma, whose drug discovery platform is based on research at UCSF, has completed a $122m initial public offering after underwriters exercised their greenshoe option.

Karolinska Development has celebrated an exit as Umeå spinout Asarina Pharma went public in Sweden after raising $16.3m in its initial public offering.

The immuno-oncology therapy developer's investors include UC’s office of the chief investment officer, which contributed to a $300m round in January.

A month after Sutro closed an $85.4m series E round, the cancer drug developer, based on research at Stanford, has filed for a $75m initial public offering.

Ascentage Pharma, based on research at University of Michigan, has filed to list in Hong Kong having raised about $235m in funding.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.